source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
MarijuanaStocks | 2021-06-24 08:00:01 | https://marijuanastocks.com/2-marijuana-stocks-to-watch-before-the-end-of-the-month/ | 2 Marijuana Stocks To Add To Next Months Watchlist The post 2 Marijuana Stocks To Watch Before The End Of The Month appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | 2 Marijuana Stocks To Watch Before The End Of The Month | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-24 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential-treatment-of-relapsed-or-refractory-multiple-myeloma-301318965.html | NORTH CHICAGO, Ill. and NEWARK, Calif. | AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-06-23 15:26:26 | https://investorplace.com/2021/06/7-overlooked-blue-chip-stocks-to-buy-for-eagle-eyed-investors/ | While the excitement in the market remains centered on meme trades, these overlooked blue-chip stocks offer much-needed stability. The post 7 Overlooked Blue-Chip Stocks to Buy for Eagle-Eyed Investors appeared first on InvestorPlace. | 7 Overlooked Blue-Chip Stocks to Buy for Eagle-Eyed Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-21 18:48:31 | https://www.zacks.com/stock/news/1743965/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed at $114.73 in the latest trading session, marking a +1.42% move from the prior day. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-21 18:12:47 | https://seekingalpha.com/article/4435924-the-fed-has-spoken-stocks-to-buy-now | The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing our sector ranking. | The Fed Has Spoken: Stocks To Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-06-20 05:11:00 | https://www.fool.com/investing/2021/06/20/how-this-1-pharma-company-can-benefit-from-its-com/ | Delays in FDA approval for Incyte could spell good news for Sanofi. | How This Pharma Company Can Benefit From Its Competitors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2021-06-19 10:10:00 | https://www.forbes.com/sites/brettowens/2021/06/19/5-safe-healthcare-dividends-yielding-55/ | Healthcare—along with consumer staples (“buying stuff”) and utilities (“keeping the lights on”)—provide portfolio stability. | 5 Safe Healthcare Dividends Yielding 5.5% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-06-19 06:36:00 | https://www.fool.com/investing/2021/06/19/warren-buffetts-highest-yielding-dividend-stocks/ | These recent additions to Berkshire Hathaway's portfolio all pay at least a 4.4% yield. | Warren Buffett's Highest-Yielding Dividend Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-18 19:20:00 | https://seekingalpha.com/article/4435611-dividend-income-summary-berts-may-2021-summary | In May, we received $581.67 in dividend income! This was a 32.19% year over year increase compared to May 2020. Until the dividend cut is finalized, we are still receiving a boatload of dividend income from AT&T. | Dividend Income Summary: Bert's May 2021 Summary | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-18 09:15:00 | https://seekingalpha.com/article/4435421-abbvie-beyond-humira-framing-a-bright-future | With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues. Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science, albeit there are plentiful clues to work with. | AbbVie: Beyond Humira, Framing A Bright Future | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-18 03:12:41 | https://seekingalpha.com/article/4435444-abbvie-is-going-to-find-it-tough-moving-on-from-humira | AbbVie Is Going To Find It Tough Moving On From Humira | AbbVie Is Going To Find It Tough Moving On From Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-18 02:42:42 | https://seekingalpha.com/article/4435438-abbvie-bargain-at-current-price-dcf-valuation | AbbVie Is A Bargain At The Current Price: DCF Valuation | AbbVie Is A Bargain At The Current Price: DCF Valuation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-17 18:29:00 | https://www.prnewswire.com/news-releases/abbvie-declares-quarterly-dividend-301315157.html | NORTH CHICAGO, Ill., June 17, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. | AbbVie Declares Quarterly Dividend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-17 14:09:43 | https://seekingalpha.com/article/4435361-abbvie-the-investors-trifecta | AbbVie is unique in the fact they offer investors growth potential, high-yield, and dividend growth. | AbbVie: The Investor's Trifecta | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-06-17 09:02:12 | https://247wallst.com/investing/2021/06/17/warren-buffet-sold-these-8-stocks-in-q1-and-all-have-done-well-in-q2/ | On Wednesday, we took a look at five of the 13 stocks in which Warren Buffett lightened or sold entirely Berkshire Hathaway Inc. | Warren Buffet Sold These 8 Stocks in Q1 and All Have Done Well in Q2 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-17 06:30:00 | https://seekingalpha.com/article/4435134-abbvie-stellar-dividend-growth-pharma-stock | ABBV is a leading biotech business and on the cusp of becoming a Dividend King. | AbbVie: A Stellar Dividend Growth Pharma Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-17 01:09:07 | https://seekingalpha.com/article/4435248-3-reasons-abbvie-is-a-dividend-champ | 3 Reasons AbbVie Is A Dividend Champ | 3 Reasons AbbVie Is A Dividend Champ | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-06-16 17:09:14 | https://www.gurufocus.com/news/1456754/4-warren-buffett-holdings-trading-at-low-pricetofree-cash-flow-ratios | According to the All-in-One Screener, a Premium feature of GuruFocus, four stocks in Berkshire Hathaway Inc.'s ( BRK.A , Financial)( BRK.B , Financial) equity portfolio that have high profitability and are trading at attractive price-to-free cash flow ratios are AbbVie Inc. ( ABBV , Financial), The Kroger Co. ( KR , Fi... | 4 Warren Buffett Holdings Trading at Low Price-to-Free Cash Flow Ratios | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-16 12:47:27 | https://www.zacks.com/stock/news/1717612/why-abbvie-abbv-is-a-great-dividend-stock-right-now | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Great Dividend Stock Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-15 05:41:53 | https://seekingalpha.com/article/4434858-spdr-s-p-biotech-etf-long-american-innovation | XBI: Long American Innovation | XBI: Long American Innovation | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-14 18:48:31 | https://www.zacks.com/stock/news/1708092/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $115.40, marking a -0.02% move from the previous day. | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-14 07:32:31 | https://www.benzinga.com/general/biotech/21/06/21545497/jnjs-imbruvica-abbvies-venclexta-combo-achieves-progression-free-survival-of-78-4-versus-gazyva-c | A combination of Johnson & Johnson's (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG's (OTC: RHHBY) Venclexta/Venclyxto (venetoclax) slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche's Gazyva and the chemotherapy chlorambucil in previously untreated chronic ... | JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-13 16:20:00 | https://seekingalpha.com/article/4434599-week-in-review-shanghai-carsgen-to-raise-400-million-in-hong-kong-ipo | Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO | Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-12 07:02:00 | https://www.prnewswire.com/news-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study-301311176.html | NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in... | IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-06-11 13:27:34 | https://247wallst.com/investing/2021/06/11/4-buy-rated-giants-pay-a-dividend-of-at-least-3/ | Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%. | 4 Buy-Rated Giants Pay a Dividend of at Least 3% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-06-11 10:00:45 | https://marijuanastocks.com/top-marijuana-stocks-to-buy-for-the-long-term-2-analyst-rate-as-a-strong-buy-right-now/ | These Stocks Could Deliver Long Term Returns For Investors The post Top Marijuana Stocks To Buy For The Long-Term? 2 Analyst Rate As A Strong Buy Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Top Marijuana Stocks To Buy For The Long-Term? 2 Analyst Rate As A Strong Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-06-11 05:55:00 | https://www.fool.com/investing/2021/06/11/3-absurdly-cheap-stocks-to-buy-in-a-ridiculously-e/ | And all three of them pay solid dividends. | 3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-11 01:03:00 | https://www.prnewswire.com/news-releases/new-data-shows-abbvies-venclyxtovenclexta-fixed-duration-combination-demonstrates-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-patients-after-three-years-off-treatment-301310501.html | NORTH CHICAGO, Ill., June 11, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated patients with chronic lymphocytic leukemia (CLL) with coexisting conditions who were treated with VENCLYXTO®/VENCLEXTA® (v... | New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-06-10 13:39:16 | https://www.youtube.com/watch?v=dAVTf1JwSM0 | The "Halftime Report" traders answer viewer questions in #AskHalftime. | Best long term hold: Abbvie or Gilead? #AskHalftime | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-06-10 06:45:00 | https://www.fool.com/investing/2021/06/10/2-top-healthcare-stocks-to-buy-in-a-market-crash/ | Buying these stocks on the dips could lead to oversized returns with very little risk. | 2 Top Healthcare Stocks to Buy in a Market Crash | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-08 12:58:06 | https://seekingalpha.com/article/4433709-abbvie-inc-abbv-management-presents-goldman-sachs-42nd-annual-global-healthcare-conference | AbbVie, Inc. (ABBV) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) | AbbVie, Inc. (ABBV) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-08 08:45:00 | https://www.prnewswire.com/news-releases/allergan-aesthetics-and-botox-cosmetic-onabotulinumtoxina-put-real-stories-at-the-forefront-in-new-campaign-301307465.html | IRVINE, Calif., June 8, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is changing the way BOTOX® Cosmetic, the #1 selling neurotoxin treatment1, is connecting with consumers. | Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-07 18:48:23 | https://www.zacks.com/stock/news/1671483/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed at $113.01 in the latest trading session, marking a +0.58% move from the prior day. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-07 14:07:06 | https://www.benzinga.com/general/biotech/21/06/21457175/abbvies-ibrutinibvenetoclax-combo-potentially-chemo-free-fixed-duration-treatment-option-in-leuke | AbbVie Inc (NYSE: ABBV) has announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating Imbruvica (ibrutinib) combined with Venclexta/Venclyxto (venetoclax) for untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Data were presented at the American Society of Clinical Oncolo... | AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-07 11:30:00 | https://www.prnewswire.com/news-releases/captivate-study-shows-an-imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-chemotherapy-free-combination-has-potential-to-provide-remission-after-fixed-duration-treatment-for-chronic-lymphocytic-leukemia-cll-301306442.html | NORTH CHICAGO, Ill., June 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination,... | CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-04 09:00:00 | https://www.prnewswire.com/news-releases/results-from-imbruvica-ibrutinib-resonate-2-study-provide-up-to-seven-years-of-progression-free-and-overall-survival-data-in-first-line-chronic-lymphocytic-leukemia-cll-301306012.html | NORTH CHICAGO, Ill., June 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymp... | Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-06-03 10:32:29 | https://www.zacks.com/stock/news/1649602/abbvies-abbv-skyrizi-succeeds-in-crohns-maintenance-study | AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study. | AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-06-02 20:18:04 | https://seekingalpha.com/article/4432748-abbvie-inc-abbv-presents-bernsteins-37th-annual-strategic-decisions-conference-transcript | AbbVie Inc. (ABBV) Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript) | AbbVie Inc. (ABBV) Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2021-06-02 14:47:00 | https://www.reuters.com/business/senate-finance-committee-launches-probe-into-abbvies-tax-practices-2021-06-02/ | Senate Finance Committee Chairman Ron Wyden has launched an investigation into AbbVie's international tax practices, saying the drugmaker has avoided paying taxes on U.S. prescription drug sales by shifting its profit overseas. | Senate Finance Committee launches probe into AbbVie's tax practices | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-06-02 10:02:24 | https://www.benzinga.com/general/biotech/21/06/21389708/abbvies-rinvoq-shows-encouraging-long-term-safety-efficacy-in-rheumatoid-arthritis-psoriatic-arth | AbbVie Inc (NYSE: ABBV) has announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with Rinvoq (upadacitinib) resulted in sustained improvements in psoriatic arthritis patients who did not respond to disease-modifying anti-rheumatic drugs. At week 56, 29% of pat... | AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-02 08:30:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-301303334.html | NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. | AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-02 08:00:00 | https://www.prnewswire.com/news-releases/phase-3-maintenance-results-show-patients-with-crohns-disease-receiving-risankizumab-skyrizi-achieved-endoscopic-response-and-clinical-remission-at-one-year-301303904.html | NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing risankizumab 360 mg (subcutaneous [SC]; administered every eight weeks) achieved the co-primary endpoints of endoscopic response and clinical remission at ... | Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-02 07:30:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-analysis-evaluating-continuous-rinvoq-upadacitinib-treatment-in-psoriatic-arthritis-for-more-than-one-year-at-eular-2021-virtual-congress-301303846.html | NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ® (upadacitinib, 15 mg, once daily) resulted in sustained improvements in disease activity for more than one year (56 we... | AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-06-02 07:00:00 | https://www.prnewswire.com/news-releases/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq-upadacitinib-in-patients-with-rheumatoid-arthritis-to-be-presented-at-eular-2021-virtual-congress-301303568.html | NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new analyses to be presented at the EULAR 2021 Virtual Congress showing patients with moderate to severe rheumatoid arthritis on background methotrexate (MTX) treated with RINVOQ® (upadacitinib, 15 mg, once daily) maintained higher ra... | New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-31 12:47:18 | https://www.zacks.com/stock/news/1634305/abbvie-abbv-is-a-top-dividend-stock-right-now-should-you-buy | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-30 05:55:00 | https://www.fool.com/investing/2021/05/30/the-smartest-dividend-stocks-to-buy-with-400-right/ | Four Benjamins will get you strong dividends and solid growth with these stocks. | The Smartest Dividend Stocks to Buy With $400 Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-05-28 14:26:23 | https://marijuanastocks.com/2-biotech-cannabis-stocks-to-watch-in-june-2021/ | 2 Biotech Cannabis Stocks To Watch Next Month As marijuana stocks continue… The post 2 Biotech Cannabis Stocks To Watch In June 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | 2 Biotech Cannabis Stocks To Watch In June 2021 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-27 22:52:34 | https://seekingalpha.com/article/4431825-the-91-best-dividend-stocks-on-earth-for-june | Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These International “Dividend Aristocrats,” have raised dividends at least five straight years (Canadian) 10 years (European Union... | The 91 'Best Dividend Stocks On Earth' For June | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-27 10:12:04 | https://www.fool.com/investing/2021/05/27/2-stocks-to-buy-with-dividends-yielding-more-than/ | In turbulent times, these two dividend giants can see you through. | 2 Stocks to Buy With Dividends Yielding More Than 3% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-05-27 07:45:59 | https://247wallst.com/investing/2021/05/27/5-high-yielding-dividend-aristocrats-may-be-the-best-stocks-to-own-now/ | We have covered the Dividend Aristocrat stocks for years here at 24/7 Wall St. So it was kind of a seismic shock when AT&T Inc. | 5 High-Yielding Dividend Aristocrats May Be the Best Stocks to Own Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-27 06:06:00 | https://www.fool.com/investing/2021/05/27/5-stocks-buffett-is-selling-you-should-be-buying/ | Warren Buffett is a legendary investor, but he's wrong to pare down these top-tier stocks. | 5 Stocks Warren Buffett Is Selling That You Should Be Buying | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-26 10:34:57 | https://www.gurufocus.com/news/1438675/abbvie-the-market-cant-see-beyond-humira | AbbVie Inc ( ABBV , Financial) has generally been associated with Humira since the company was spun off from Abbott Laboratories ( ABT , Financial) in early 2013. Humira has been one of the world's best-selling drugs over the past few years, but it is experiencing patent expirations in certain markets and will also see... | AbbVie: The Market Can't See Beyond Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-26 10:31:06 | https://www.zacks.com/stock/news/1608824/abbvies-abbv-venclyxto-gets-eu-nod-for-first-line-aml | European Commission grants approval to AbbVie (ABBV)/Roche's Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia | AbbVie's (ABBV) Venclyxto Gets EU Nod for First-Line AML | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-26 08:15:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-bernsteins-37th-annual-strategic-decisions-conference-301299171.html | NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Wednesday, June 2, 2021. | AbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-26 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting-301299437.html | NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually June 3-6. | AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-25 17:20:06 | https://seekingalpha.com/article/4431244-abbvie-inc-abbv-2021-ubs-global-healthcare-virtual-conference-call-transcript | AbbVie Inc. (ABBV) at 2021 UBS Global Healthcare Virtual Conference Call - (Transcript) | AbbVie Inc. (ABBV) at 2021 UBS Global Healthcare Virtual Conference Call - (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-05-25 11:28:35 | https://www.benzinga.com/general/biotech/21/05/21279582/abbvie-roche-win-european-approval-for-venclyxto-in-newly-diagnosed-acute-myeloid-leukemia | The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). Venclyxto is approved in combination with a hypomethylating agent, azacitidine or decitabine, in AML patients ineligible for intensive chemotherapy... | AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-25 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-in-combination-with-a-hypomethylating-agent-for-patients-with-newly-diagnosed-acute-myeloid-leukemia-who-are-ineligible-for-intensive-chemotherapy-301298689.html | NORTH CHICAGO, Ill., May 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who a... | AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-24 09:15:00 | https://www.prnewswire.com/news-releases/abbvie-presents-new-late-breaking-data-analyses-showing-risankizumab-skyrizi--achieves-clinical-remission-and-endoscopic-response-at-week-12-in-patients-with-moderate-to-severe-crohns-disease-301297664.html | NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risan... | AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-24 08:45:00 | https://www.prnewswire.com/news-releases/the-lancet-publishes-results-from-pivotal-global-phase-3-program-evaluating-rinvoq-upadacitinib-in-atopic-dermatitis-301297423.html | NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ® (upadacitinib) in adults and adolescents with moderate to severe atopic dermatit... | The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-05-24 08:16:03 | https://www.benzinga.com/general/biotech/21/05/21252013/jnjs-stelara-fails-to-beat-abbvies-humira-in-crohns-disease-patients | The Janssen Pharmaceutical Companies, a unit of Johnson & Johnson (NYSE: JNJ), announced efficacy and safety data for Stelara (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC), including data from the SEAVUE study, a head-to-head study of biologic therapies. Data were presented at the Clinical Science L... | JNJ's Stelara Fails to Beat AbbVie's Humira In Crohn's Disease Patients | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-23 05:52:00 | https://www.fool.com/investing/2021/05/23/the-best-dividend-aristocrats-to-buy-with-500-righ/ | You'll even have a little cash left over after buying these great dividend stocks. | The Best Dividend Aristocrats to Buy With $500 Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-22 07:11:00 | https://www.fool.com/investing/2021/05/22/these-top-3-healthcare-dividend-stocks-will-carry/ | Regular payouts can carry a lot of weight for a portfolio. | These Top 3 Healthcare Dividend Stocks Will Carry You Through Any Market Mood | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-21 09:15:00 | https://seekingalpha.com/article/4430384-five-high-yield-income-stock-picks-with-upside-potential | 5 Most Rewarding High-Yield Income Stocks With More Upside Potential | 5 Most Rewarding High-Yield Income Stocks With More Upside Potential | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-21 06:43:00 | https://www.fool.com/investing/2021/05/21/2-healthcare-stocks-perfect-to-buy-now-and-hold-un/ | Here's why you should consider buying into these two companies for the long run. | 2 Healthcare Stocks Perfect to Buy Now and Hold Until Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-20 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-ubs-global-healthcare-virtual-conference-301295596.html | NORTH CHICAGO, Ill., May 20, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. | AbbVie to Present at the UBS Global Healthcare Virtual Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-05-19 14:48:06 | https://investorplace.com/2021/05/7-best-long-term-dividend-stocks-for-your-retirement-portfolio/ | Given the low interest rate environment, investors look for dividend shares. Here are seven long-term stocks for retirement portfolios. | 7 Best Long-Term Dividend Stocks for Your Retirement Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2021-05-19 10:20:07 | https://marijuanastocks.com/should-you-go-long-on-these-top-marijuana-stocks-to-buy/ | Marijuana Stocks To Watch For Long Term Investing The post Should You Go Long On These Top Marijuana Stocks To Buy? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Should You Go Long On These Top Marijuana Stocks To Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-19 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-showcase-breadth-of-oncology-portfolio-and-pipeline-at-the-2021-asco-and-eha-annual-congresses-301294521.html | NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17). | AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-18 22:38:07 | https://seekingalpha.com/article/4429850-abbvie-inc-abbv-presents-2021-rbc-capital-markets-global-healthcare-conference-transcript | AbbVie Inc. (ABBV) Presents at 2021 RBC Capital Markets Global Healthcare Conference (Transcript) | AbbVie Inc. (ABBV) Presents at 2021 RBC Capital Markets Global Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2021-05-18 17:47:21 | https://www.benzinga.com/general/biotech/21/05/21181651/abbvie-inflated-prices-for-two-major-drugs-engaged-in-anticompetitive-practices-house-oversight-r | AbbVie Inc (NYSE: ABBV) significantly inflated prices over the past two decades for patients in the U.S. who take the drugs Humira and Imbruvica, a report released by the House Oversight and Reform Committee found. The committee concluded that the price increases led to billions of dollars in corporate revenue and heft... | AbbVie Inflated Prices For Two Major Drugs, Engaged In Anticompetitive Practices, House Oversight Report Says | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2021-05-18 16:44:00 | https://www.marketwatch.com/story/house-committee-takes-on-abbvies-pricing-patents-for-top-selling-drug-humira-11621370672 | AbbVie Inc.'s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs. | The Wall Street Journal: House Committee takes on AbbVie's pricing, patents for top-selling drug Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-18 09:28:10 | https://www.fool.com/investing/2021/05/18/after-a-blowout-quarter-is-abbvie-stock-a-buy/ | In recent earnings results, it stood out among its peers. | After a Blowout Quarter, Is AbbVie Stock a Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-16 21:34:53 | https://seekingalpha.com/article/4429188-3-reasons-abbvie-is-one-of-the-best-buffett-blue-chip-bargains-on-wall-street | Speculative manias are all around us, from Dogecoin recently surpassing $100 billion in market cap to the S&P 500 becoming 38% overvalued. Fortunately, wonderful blue-chip bargains are always available, if you know where to look. | 3 Reasons AbbVie Is One Of The Best Buffett Blue-Chip Bargains On Wall Street | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-16 06:01:00 | https://www.fool.com/investing/2021/05/16/3-high-yield-dividend-stocks-id-buy-right-now/ | Their great dividends should be rock-solid. | 3 High-Yield Dividend Stocks I'd Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-14 12:47:16 | https://www.zacks.com/stock/news/1551458/why-abbvie-abbv-is-a-top-dividend-stock-for-your-portfolio | Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? | Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-14 06:20:00 | https://www.fool.com/investing/2021/05/14/3-dividend-stocks-that-pay-you-better-than-coca-co/ | Income investors will find plenty to like about these reliable and generous dividend payers. | 3 Dividend Stocks That Pay You Better Than Coca-Cola Does | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Insider | 2021-05-13 10:43:46 | https://www.businessinsider.com/alvogen-chairman-interview-suing-abbvie-humira-biosimilar-2021-5 | Pressure is rising on AbbVie as the $203 billion pharmaceutical company faces congressional scrutiny and a new legal battle over the core of its business. The Icelandic generic-drug specialist Alvotech launched a legal battle this week against AbbVie, challenging the patents that protect its best-selling medicine, Humi... | AbbVie faces the biggest challenge yet to its best-selling medicine, Humira, as an unlikely Icelandic drugmaker launches a legal fight over 'outrageous' patents | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Business Wire | 2021-05-12 17:27:00 | https://www.businesswire.com/news/home/20210512006041/en/SOLITON-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Soliton-Inc.---SOLY/ | NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Soliton, Inc. (NasdaqGS: SOLY) to AbbVie, Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Soliton will r... | SOLITON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Soliton, Inc. - SOLY | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2021-05-12 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-rbc-capital-markets-global-healthcare-conference-301289262.html | NORTH CHICAGO, Ill., May 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021. | AbbVie to Present at the RBC Capital Markets Global Healthcare Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-11 19:32:13 | https://www.zacks.com/stock/news/1537471/3-strong-dividend-stocks-to-buy-for-market-volatility-and-inflation-fears | Let's dive into three strong dividend-paying stocks that could be solid long-term holds. | 3 Strong Dividend Stocks to Buy for Market Volatility and Inflation Fears | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-11 14:12:11 | https://www.gurufocus.com/news/1423501/abbvie-enters-growing-market-for-tattoo-removal-cellulite-treatment | "What were you inking?" | AbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-08 07:45:00 | https://seekingalpha.com/article/4425879-10-best-value-picks-among-dividend-aristocrats | Dividend Aristocrats can be a great choice for investors looking for reliable income and stocks that can outperform during a recession. Not all Dividend Aristocrats are necessarily attractive at the same time, however. | 10 Of The Best Value Picks Among Dividend Aristocrats | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-08 06:25:00 | https://www.fool.com/investing/2021/05/08/is-it-too-late-to-buy-abbvie-stock-in-2021/ | It might not be too late to pick up shares of the big pharma company. | Is It Too Late to Buy AbbVie Stock in 2021? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-05-08 06:04:00 | https://www.fool.com/investing/2021/05/08/better-dividend-stock-abbvie-or-pfizer/ | Both big pharmaceutical companies have a lot to offer income investors. | Better Dividend Stock: AbbVie or Pfizer? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-07 17:36:21 | https://www.gurufocus.com/news/1420109/guess-which-stocks-warren-buffett-bought-1stquarter-contest | GuruFocus runs a contest every quarter in which people guess the stocks they think Warren Buffett (Trades, Portfolio) might have bought. | Guess Which Stocks Warren Buffett Bought: 1st-Quarter Contest | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-05-07 13:13:44 | https://investorplace.com/2021/05/7-warren-buffett-stocks-to-buy-for-next-decade/ | As one of the world's greatest investors, Warren Buffett knows a thing or two about acquiring the best stocks to buy. The post 7 Warren Buffett Stocks to Buy for the Next Decade appeared first on InvestorPlace. | 7 Warren Buffett Stocks to Buy for the Next Decade | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-05 15:40:55 | https://www.gurufocus.com/news/1417090/diamond-hill-capital-reveals-top-1stquarter-trades | Earlier this week, investment firm Diamond Hill Capital (Trades, Portfolio) disclosed its portfolio for the first quarter, which ended March 31. | Diamond Hill Capital Reveals Top 1st-Quarter Trades | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-05-05 13:38:59 | https://www.youtube.com/watch?v=0BAdwG_6e98 | The "Halftime Report" traders answer viewer questions in #AskHalftime. | Buy, sell or hold AbbVie? #AskHalftime | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-05 12:24:28 | https://www.zacks.com/stock/news/1504919/has-abbvie-abbv-outpaced-other-medical-stocks-this-year | Is (ABBV) Outperforming Other Medical Stocks This Year? | Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-04 22:26:24 | https://seekingalpha.com/article/4424316-philip-morris-enbridge-abbvie-prudential-manulife-high-yield-esg-blue-chips-for-a-rich-retirement | ESG investing has become red hot in recent years, and $20 trillion of assets are expected to flow into ESG funds in the next two decades. Some think ESG is the newest alpha factor. Thus far studies show it's merely an indicator of overall fundamental risk and quality, similar to credit ratings. | 5 High-Yield ESG Blue-Chips For A Safe And Prosperous Retirement | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-04 18:47:38 | https://www.zacks.com/stock/news/1500786/abbvie-abbv-stock-moves-061-what-you-should-know | AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day. | AbbVie (ABBV) Stock Moves -0.61%: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-04 03:37:15 | https://seekingalpha.com/article/4423926-kiplinger-barrons-75-top-stocks-for-2021-show-17-may-flies | October-December Kiplinger Today published four articles: 11 Best Monthly Dividend[s], 21 Best Stocks, 11 Dividend Growth Stocks, and 25 Dividend Stocks Analysts Love. Stocks therein I called "Kiplinger Top Stocks For 2021." Then, in March, Barron's Weekly published Retire on Dividends listing 10 to start. All told, fi... | Kiplinger And Barron's 75 Top Stocks For 2021 Show 17 As May Flies | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-03 17:40:14 | https://www.gurufocus.com/news/1414257/abbvies-humira-still-number-1-in-drug-sales | Humira retained the top spot on the list of the top 20 selling drugs in 2020. The AbbVie , Financial)">Inc.( ABBV , Financial) mega-blockbuster generated revenue of nearly $20.4 billion last year, according to an article in FierceBiotech, which worked with Evaluate Pharma to compile the list. | AbbVie's Humira Still Number 1 in Drug Sales | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-05-03 14:25:31 | https://investorplace.com/3-top-stock-trades-for-the-new-week/ | This week's top stock trades include three low-risk entries for bulls: NUE, AEM and ABBV. This trio boasts better patterns than the S&P 500. | 3 Top Stock Trades for the Week | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-05-03 11:16:21 | https://www.zacks.com/commentary/1492454/3-big-drugmaker-stocks-to-watch-out-for-amid-pandemic-woes | 3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes | 3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-05-03 09:47:55 | https://www.gurufocus.com/news/1413770/3-highyield-stocks-for-dividend-investors- | The following three stocks may be of interest to dividend investors, as they are offering much higher dividend yields than the S&P 500 Index. The benchmark index's dividend yields 1.38% as of Friday, April 30. | 3 High-Yield Stocks for Dividend Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-02 23:16:37 | https://seekingalpha.com/article/4423651-abbvie-a-money-minting-machine | While only the U.S. Department of Treasury is authorized to mint paper and coin money, there are some publicly traded businesses that figuratively do so with their high margins. One such business is AbbVie, which generated a staggering net margin (net earnings/net revenues) of 27.3% during Q1 2021. | AbbVie: A Money Minting Machine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-05-02 21:50:35 | https://seekingalpha.com/article/4423647-abbvies-earnings-beat-reaffirms-bullish-outlook | AbbVie just reported solid quarterly performance. The stock is cheap relative to (admittedly modest) expected earnings. | AbbVie's Earnings Beat Reaffirms A Bullish Outlook | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-05-02 08:22:22 | https://pulse2.com/abbv-stock-nyse-abbvie-124-target-up-from-120-by-piper-sandler/ | The shares of AbbVie Inc (NYSE: ABBV) have received a price target increase from $120 to $124 by Piper Sandler. These are the details. | ABBV Stock: $124 Target (Up From $120) By Piper Sandler | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.